GlassScriptPhysician profile
Kelli E Woltemath
NPI 1285606731
$1,294.84
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.32 · 2020: $161 · 2021: $393 · 2022: $367 · 2023: $273 · 2024: $52.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189 · Debt Forgiveness: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $189.39 |
| Debt Forgiveness | $136.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $233.69 | 2022-2023 | |
| Mylan Specialty L.P. | $207.77 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $161.35 | 2020 | |
| Novo Nordisk INC | $159.74 | 2021-2023 | Rybelsus, Ozempic |
| Welch Allyn | $136.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $109.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.04 | 2021-2022 | |
| Abbvie INC. | $50.19 | 2021-2023 | Ubrelvy |
| Pfizer INC. | $40.17 | 2021-2023 | |
| Lilly USA, LLC | $33.80 | 2023-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $18.66 | 2022 | |
| Daiichi Sankyo INC. | $16.99 | 2023 | Injectafer |
| Astellas Pharma US INC | $15.62 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $13.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.75 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Woltemath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.